Indivior Pharmaceuticals, Inc.

Indivior develops, manufactures, and sells prescription drugs to treat opioid dependence and related disorders globally. Core products include SUBLOCADE injections, SUBOXONE Film/TABLET, and SUBUTEX Tablet for opioid use disorder. The company also offers OPVEE nasal spray for overdose reversal. Indivior is developing INDV-2000 for moderate to severe OUD and INDV-6001 with Alar Pharmaceuticals Inc.

Overview

Sector

Pharmaceutical

Target Price

21.9 USD

Current Price

37.4 USD

Potential

-41%

Strengths

The company has low debt. Net Debt to EBITDA Ratio is 0.40 and it is lower than the sector mean.
EV/EBIT (15.47) is lower than the sector mean.
Strong EBITDA Margin of 24.78%.

Weaknesses

With a depreciation Potential of -36.02%, based on our fundamental analysis, it suggests the stock may be overvalued.
The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (14.71%).
The Price to Free Cash Flow ratio (100.00) is significantly higher than the sector mean.

Indicator	Value
PER	21.9
EV/EBITDA	15.4
Price/Free Cash Flow'	100.0
ROIC	-%
Net Debt/EBITDA	0.4

Indivior Pharmaceuticals, Inc.

Overview

Strengths

Weaknesses

Key Financial Data